Press-release for stocks for FNCTF

Prices are updated after-hours

symbols : FNCTF source : Www.biospace.com

save search

Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection
Published: 2024-04-19 (Crawled : 22:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| Email alert Add to watchlist
infection antibiotics trials for

Terran Biosciences Granted US Patent for the World’s First New Forms of MDMA, Potentially Clearing the Path to a Future 505(b)(2) Approval
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| Email alert Add to watchlist
first patent granted approval for

Allergan Aesthetics and University Lab Partners Announce the Golden Ticket Pitch Competition to Accelerate Aesthetics Start-Ups
Published: 2024-04-12 (Crawled : 21:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| Email alert Add to watchlist

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| -1.12% | O: -100.0% H: NaN% C: Infinity%
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| -1.79% | O: 0.5% H: 0.83% C: 0.28%
CTXR | $0.7477 -7.18% -7.73% 1.7M

Health Technology

| -11.81% | O: 2.33% H: 2.28% C: -4.23%
hope treatment pharmaceuticals city for car-t trial

GammaTile® Marks Milestone: 100th Patient Enrolled in Groundbreaking ROADS Phase 3 Clinical Trial for Newly Diagnosed Metastatic Brain Tumors
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| -4.0% | O: 0.17% H: 0.0% C: -0.43%
gammatile tumors for trial

UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
URGN | $13.78 -3.37% -3.48% 390K

Health Technology

| 1.7% | O: -0.64% H: 0.71% C: -2.43%
pharma patent pharmaceuticals teva

Biological Dynamics Announces Expanding Adoption of ExoVerita™ Pro Under Early Access Program
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| -1.91% | O: -100.0% H: NaN% C: Infinity%
pro program

Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M

Health Technology

| 1.23% | O: -0.13% H: 0.4% C: -0.06%
ylynk-006 keytruda lung merck update cancer cell trial plus

Newron Presents 2023 Financial Results and Provides 2024 Outlook
Published: 2024-03-19 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| Email alert Add to watchlist
financial results

RedHill Announces New USPTO Patent Covering Talicia® Through 2034
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
RDHL | $0.4519 7.39% 6.88% 330K

Health Technology

| -27.1% | O: 1.1% H: 3.68% C: 1.65%
talicia patent

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| Email alert Add to watchlist
cld-101 california institute hope cancer city funding

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
Published: 2024-03-07 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| -3.03% | O: 0.79% H: 0.78% C: 0.78%
MBIO | $0.3451 -6.98% -7.51% 130K

Health Technology

| -71.21% | O: 8.33% H: 4.2% C: -2.8%
FBIO | $1.765 -2.49% -2.55% 190K

Health Technology

| -20.54% | O: 2.93% H: 0.0% C: -9.21%
tumors cell city trial therapy

Harvard Eye Associates Now Offering iDose(R) TR as a New Treatment Option to Reduce Eye Pressure in Patients With Ocular Hypertension and Open-Angle Glaucoma
Published: 2024-02-20 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| Email alert Add to watchlist
glaucoma ocular offering treatment hypertension eye

Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st
Published: 2024-01-29 (Crawled : 17:00) - biospace.com/
NTRB | $3.91 -3.22% -3.32% 26K

Manufacturing

| 61.13% | O: 0.38% H: 2.44% C: 2.44%
conference atlantic city microcap

Gamida Cell Actively Pursuing Strategic Alternatives - Jan 29, 2024
Published: 2024-01-29 (Crawled : 13:00) - biospace.com/
MC | $51.65 1.33% 0.0% 590K

Finance

| -7.46% | O: -0.04% H: 4.19% C: 4.15%
cell